Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up
- 1 March 2021
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (3), 844-846
- https://doi.org/10.2337/dc20-1809
Abstract
OBJECTIVE To analyze safety and efficacy of the Diabeloop Generation 1 (DBLG1) hybrid closed-loop artificial pancreas system in patients with type 1 diabetes in real-world conditions. RESEARCH DESIGN AND METHODS After a 1-week run-in period with their usual pump, 25 patients were provided the commercial DBLG1 system. The results are presented on time in range (TIR) and HbA(1c) over 6 months. RESULTS The mean (SD; range) age of patients was 43 (13.8; 25-72) years. At baseline, the mean HbA(1c) and TIR 70-180 mg/dL were, respectively, 7.9% (0.93; 5.6-8.5%) [63 mmol/mol (10; 38-69 mmol/mol)] and 53% (16.4; 21-85%). One patient stopped using the system after 2 months. At 6 months, the mean HbA(1c) decreased to 7.1% [54 mmol/mol] (P < 0.001) and TIR 70-180 mg/dL increased to 69.7% (P < 0.0001). TIR <70 mg/dL decreased from 2.4 to 1.3% (P = 0.03), and TIR <54 mg/dL decreased from 0.32 to 0.24% (P = 0.42). No serious adverse event was reported during the study. CONCLUSIONS The ability of the DBLG1 system to significantly improve glycemic control in real-world conditions, without serious adverse events, was confirmed in this follow-up study.This publication has 7 references indexed in Scilit:
- Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ TechnologyDiabetes Technology & Therapeutics, 2021
- Long‐term real‐life glycaemic outcomes with a hybrid closed‐loop system compared with sensor‐augmented pump therapy in patients with type 1 diabetesDiabetes, Obesity and Metabolism, 2019
- Efficacy of the Diabeloop closed‐loop system to improve glycaemic control in patients with type 1 diabetes exposed to gastronomic dinners or to sustained physical exerciseDiabetes, Obesity and Metabolism, 2019
- One Year Clinical Experience of the First Commercial Hybrid Closed-Loop SystemDiabetes Care, 2019
- Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in RangeDiabetes Care, 2019
- Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trialThe Lancet Digital Health, 2019
- Customization of home closed-loop insulin delivery in adult patients with type 1 diabetes, assisted with structured remote monitoring: the pilot WP7 Diabeloop studyActa Diabetologica, 2018